Labcorp announces q3 results and updates 2019 guidance

Labcorp announces 2019 third quarter results and updates 2019 guidance.q3 adjusted earnings per share $2.90.q3 earnings per share $2.25.q3 earnings per share estimate $2.85 -- refinitiv ibes data.sees fy 2019 adjusted earnings per share $11.20 to $11.30.labcorp - 2019 free cash flow guidance of $950 million to $1.05 billion, up 3% to 13% over 2018.labcorp - q3 revenue of $2.9 billion, up 3.4% over $2.8 billion last year.labcorp - labcorp diagnostics revenue for quarter was $1.76 billion, an increase of 0.4%.q3 revenue view $2.91 billion -- refinitiv ibes data.labcorp - covance drug development revenue for quarter was $1.18 billion, an increase of 8.7%.labcorp sees 2019 revenue growth of 1.5% to 2.0% over 2018 revenue of $11.33 billion.labcorp - covance drug development backlog at end of quarter was $10.71 billion compared to $10.29 billion last quarter.labcorp - 2019 revenue in labcorp diagnostics is expected to be down 1.5% to down 0.5% as compared to 2018 revenue of $7.03 billion.labcorp sees 2019 revenue growth in covance drug development of 5.5% to 7.5% over 2018 revenue of $4.31 billion.fy2019 revenue view $11.48 billion -- refinitiv ibes data.fy2019 earnings per share view $11.27 -- refinitiv ibes data.
LH Ratings Summary
LH Quant Ranking